ST-630 hexafluoro vitamin D3: Phase Ib

DSCO completed placebo-controlled Phase Ib pharmacokinetic testing of rising single and multiple doses up to 0.3125 µg of its vitamin D analog, with no transient or persistent hypercalcemia. ...